Report

Authenticity Check
CID : 2333623093
Name : MS.SAYLI NARALE
Use a QR Code Scanner
Age / Gender : 25 Years / Female Application To Scan the Code
Consulting Dr. : DR.APARNA PATIL Collected : 02-Dec-2023 / 14:54

Reg. Location : Ambernath, Gemini Healthcare Reported : 02-Dec-2023 / 21:47
HEPATITIS "B" SURFACE ANTIGEN (HBsAg)

PARAMETER RESULTS BIOLOGICAL REF RANGE METHOD
Hepatitis "B" Surface Antigen Nonreactive(0.34) Reactive (>/= 1.00 Index) CMIA
(HBsAg), Serum Non-Reactive (< 1.00 Index)
Note: Kindly note in change in method w.e.f.28-04-2023
Clinical Significance:
HBsAg is the surface antigen of Hepatitis B.
It is used to diagnose Hepatitis B infection, carriers of HBV, to assess the progression and prognosis of disease process and to screen
blood donors.
HBsAg is the first serological marker after infection with HBV, appearing 1-10 weeks after exposure and 2-8 weeks after onset of
clinical symptoms.
HBsAg persists during acute phase and clears during convalescence period.
Failure to clear HBsAg within 6 months indicates a chronic carrier state.
Hepatitis B causes infection of the liver with clinical features ranging from absent or mild disease to severe liver failure.
Hepatitis B is transmitted primarily by body fluids, especially serum. It can also spread by sexual contact and from mother to fetus.
In most patients, HBV hepatitis is self limited and patient recovers; about 1-2 % of normal adolescents and adults have persistent viral
replication resulting in chronic hepatitis.
Reflex Tests:
1. HBV DNA
2. Anti HBcIgM
3. HBeAg and Anti HBe
Limitations of the test:
Heterophile antibodies in human serum can react with reagent immunoglobulins, interfering with in vitro immunoassays.
Patients routinely exposed to animals or animal serum products can be prone to this interference.
Reference:
HBsAg (Generation II) kit pack insert
Bakerman's ABC's of Interpretive Laboratory Data
Wallach's Interpretation of Diagnostic Tests
Henry's Clinical Diagnosis and Management by Laboratory methods
*Sample processed at SUBURBAN DIAGNOSTICS (INDIA) PVT. LTD SDRL, Vidyavihar Lab
*** End Of Report ***
Dr.SUHAS SAKHARE
M.D. (PATH)
Pathologist
Page 1 of 1
Ms. SAYLI N RALE Reference: DR.APARNA PATIL VID: 230067502234089
.. Sample Collected At: Registered On:
Sanjay Arora Dr.-andheri-20
03/12/2023 02:24 PM
Suburban Diag.[i] Pvt. Ltd. 2nd Floor
PID NO: P10423514870752 Sunshine Opp.shastri Nagar Andheri Collected On:
Age: 25 Year(s) Sex: Female WZone: W-16a(20) 03/12/2023 2:23PM
Processing Location:- Metropolis Reported On:
Healthcare Ltd,Unit No409-416,4th
Floor,Commercial Building-1,Kohinoor 06/12/2023 04:44 PM
Mall,Mumbai-70
Investigation Observed Value Unit Biological Reference Interval

TPMT Enzyme Activity (Thiopurine 96.9 units Low Activity: < 5.5
Methyl Transferase) Intermediate Activity: 5.5-15.5
(EDTA PLASMA,EIA) High Activity: > 15.5
Interpretation:
1. TPMT enzyme levels below 5.5 Units indicate very low TMPT activity,indicating a possible homozygous deficiency genomic
type.
2. Levels between 5.6 - 15.5 units indicate medium TPMT activity indicating possible heterozygous deficiency type.
3. Level above 15.6 Units indicate normal to high TPMT activity,indicating a possible wilde (normal) genomic type. Thiopurine
drugs exhibit severe toxicity mainly the gastrointestinal intolerance,Cytopenia or bone marrow suppression which is usually
life Threatening. These drugs require conversion to thioguanine nucleotides to exert their therapeutic (cytotoxic) effect ;
however , the conversion can be blocked by methylation or oxidation. The methylation pathway depends on thiopurine
methyltransferase ( TPMT ) activity.
4. The TPMT enzyme catalysis the S-methylation of thiopurine drugs.
TPMT activity varies among individuals:
Approximately 89% have normal activity,11% Have intermediate activity, and 0.3% have low or no detectable activity.Thioguanine
Nucleotides can accumulate in patients who have reduced TPMT activity and who are Receiving standard thiopurine doses,
resulting in hematopoietic toxicity (e.g., myelosuppression). Dosage reduction can minimize toxicity in such patients, Phenotypic test
utilizes competitive immunoassay for semi quantitative determination of TPMT activity in erythrocytes. One unit of TPMT is defined
as a formation of 1 nmol Of 6-MMP per ml of packed red blood cells per 60 mins at 37°.
-- End of Report --
Tests marked with NABL symbol are accredited by NABL vide Certificate no MC-2139; Validity till 01-06-2024
Page 1 of 1
Dr. ALAP CHRISTY
MBBS, MD, PGDM-HC Head -
Clinical Chemistry
Reg No.2020/12/6991
Name : Ms. SAYLI NARALE Age : 25 Years
Lab No. : 456657702 Gender : Female
Ref By : Dr. APARNA PATIL Reported : 5/12/2023 5:58:35PM
Collected : 3/12/2023 12:33:00PM Report Status : Final
A/c Status : P
Collected at : SUBURBAN DIAGNOSTICS ANDHERI WEST Processed at : LPL-NATIONAL REFERENCE LAB
1st Floor & Shop no 9, C-Wing, Skyline Wealth National Reference laboratory, Block E,
Space, Skyline Oasis, Primier Road, Vidhyavihar Sector 18, Rohini, New Delhi -110085
W, Mumbai-400086, Near D-Mart.
Test Report
Test Name Results Units Bio. Ref. Interval
AUTOIMMUNE BULLOUS DERMATOSES PROFILE

(IFA)
BP 230 Negative Negative
Desmoglien 1 Positive Negative
Desmoglein 3 Positive Negative
Titer 1:10
Page 1 of 5
Name : Ms. SAYLI NARALE
Lab No. : 456657702 Age : 25 Years
Ref By : Dr. APARNA PATIL Gender : Female
Collected : 3/12/2023 12:33:00PM Reported : 5/12/2023 5:58:35PM
A/c Status : P Report Status : Final
Test Report
CYTOMEGALOVIRUS, INTERFERON GAMMA RELEASE ASSAY (IGRA)

(EIA)
CMV Antigen tube Minus Nil Tube 0.44 IU/mL <0.2
Mitogen tube Minus Nil Tube 3.04 IU/mL >0.5
Final Result Positive
Interpretation
| TUBE | REMARKS |
|-----------------------|----------------------------------------------------------------|
| Nil | Represents negative control which rules out the preexisting |
| | immune response due to heterophile antibody or non-specific |
| | gamma interferon production. |
|-----------------------|----------------------------------------------------------------|
| Mitogen minus Nil | Represents positive control demonstrating successful |
| | lymphocyte activity. |
|-----------------------|----------------------------------------------------------------|
| CMV Antigen minus Nil | Detects CD8+ lymphocyte reactivity, stimulated by CMV antigens.|
Result
| RESULT | REMARKS |
|---------------|----------------------------------------------------------------------|
| | Indicates presence of IFN-Gamma response to CMV antigens. It helps in|
| | dpredicting the risk of new and recurrent CMV disease following |
| Positive | transplantation (solid organ & haematological), guides in therapeutic|
| | decision making regarding prophylaxis and preemptive therapies, risk |
| | risk stratification of patients before transplantation and improving |
| | patient health. |
|---------------|----------------------------------------------------------------------|
| | Indicates absence of IFN-Gamma response to CMV antigens in patient’s |
| Negative | sample but does not exclude the possibility of CMV disease. Such |
| | patients undergoing Solid organ transplant are vulnerable to develop |
| | CMV infection |
|---------------|----------------------------------------------------------------------|
| Indeterminate | Indicates that IFN-Gamma Response to CMV antigens and Mitogen cannot |
| | be detected and may be related to the immune status of the individual|
Note
1. CMV serology is widely used pre-transplantation to establish risk of CMV complications post
Page 2 of 5
Lab No. : 456657702 Age : 25 Years
Test Report

transplantation, but has limited value post-transplantation. Pre-transplant negative CMV-IGRA
recipients who receive an organ from a CMV-seropositive donor have a 10-fold increase of CMV
replication compared to a pre-transplant CMV-IGRA Positive recipient.
2. Solid Organ Transplant patients with CMV-IGRA Positive result at completion of anti-CMV prophylaxis
have a significantly lower rate of late onset disease compared with those having a negative CMV-
IGRA result.
3. Higher risk transplant patients with a Positive CMV-IGRA result any time post prophylaxis have a 90%
chance of remaining free from CMV disease.
4. CMV-IGRA may prove useful in the prediction of spontaneous viral clearance compared to CMV
disease progression following elevations in CMV viraemia. Higher incidence of post solid organ
transplant CMV replication was seen in recipients with a negative CMV -IGRA result compared to
recipients with a Positive result.
5. CMV-IGRA is also used in haematological transplantation.
6. This test should not be used for diagnosis of CMV infection as a negative result does not exclude
CMV disease.
7. Test conducted on plasma.
Comment
Human Cytomegalovirus (CMV) represents one of the primary opportunistic pathogens and is a leading
cause of morbidity and mortality in Solid organ transplant recipients. It is a frequently occurring complication
of immunosuppression, particularly after transplantation. Pre-emptive or prophylactic antiviral therapy has
effectively reduced the impact and incidence of symptomatic CMV infection. Cell-mediated immunity (CMI),
and specifically CMV-specific CD4+ and CD8+ T-cell response, is able to control viral replication and thus
the onset of symptomatic infections.
CMV-IGRA in combination with quantitative monitoring of viral load in blood is recommended in CMV
Consensus Guidelines on the management of CMV in solid organ transplant patients. Transplant recipient
patients who have low or declining viral load in presence of positive CMV-IGRA may indicate a low risk of
disease and possible opportunity to stop antiviral therapy and adjust immunosuppressive treatment. On the
other hand transplant recipient patients who have high or increasing viral load in presence of negative
CMV-IGRA may indicate a high risk of CMV complications and the need to start or continue antiviral therapy,
begin cellular adoptive immunotherapy and adjust the immunosuppressive drugs.
In hematopoietic stem cell transplantation (HSCT), reactivation of latent virus is more common than
acquisition of primary infection. Preventing reactivation requires a robust T cell mediated immune reponse.
Immunosuppression and T cell depleting protocols used pre-HSCT, affect the risk of reactivation.
HLA-mismatched transplants where immunosuppression is increased and GVHD is more likely, are
Page 3 of 5
Lab No. : 456657702 Age : 25 Years
Test Report

particularly susceptible to reactivate CMV, and have a survival disadvantage. Pre-transplant screening and
pre-emptive therapy based on CMV viral load are employed routinely by transplant centres. Demonstration of
a CMV-specific T cell response may help to select patients who do not require continual treatment, assist
therapeutic decisions regarding anti-viral drug use (reducing unnecessary drug toxicities and
myelosuppressive side effects) and donor T cell infusions.
Dr Ajay Gupta Dr Sarita Kumari Lal Dr Shalabh Malik Dr Puneeta Singh

MD, Pathology MD, Pathology MD, Microbiology Ph.D (Microbiology)
Technical Director - Hematology & Consultant Pathologist Technical Director - Microbiology, Principal Research Scientist
Immunology Dr Lal PathLabs Ltd Infectious Disease Molecular & NRL - Dr Lal PathLabs Ltd
NRL - Dr Lal PathLabs Ltd Serology, Clinical Pathology
NRL - Dr Lal PathLabs Ltd
Dr Sunanda
MD, Pathology
Sr. Consultant Pathologist -
Hematology & Immunology
-------------------------------End of report --------------------------------
Page 4 of 5
Lab No. : 456657702 Age : 25 Years
Test Report

IMPORTANT INSTRUCTIONS
 Test results released pertain to the specimen submitted .All test results are dependent on the quality of the sample received by the Laboratory .
 Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring Physician .Report
delivery may be delayed due to unforeseen circumstances. Inconvenience is regretted .Certain tests may require further testing at additional cost for
derivation of exact value. Kindly submit request within 72 hours post reporting.Test results may show interlaboratory variations .The Courts/Forum
at Delhi shall have exclusive jurisdiction in all disputes /claims concerning the test(s) & or results of test(s).Test results are not valid for medico legal
purposes.This is computer generated medical diagnostic report that has been validated by Authorized Medical Practitioner /Doctor.The report does
not need physical signature.
(#) Sample drawn from outside source.
If Test results are alarming or unexpected, client is advised to contact the Customer Care immediately for possible remedial action.
Tel: +91-11-49885050,Fax: - +91-11-2788-2134, E-mail: lalpathlabs@lalpathlabs.com
National Reference lab, Delhi, a CAP (7171001) Accredited, ISO 9001:2015 (FS60411) & ISO 27001:2013 (616691) Certified laboratory.
Page 5 of 5
.
Name : Ms. SAYLI NARALE Age : 25 Years

Lab No. : 456657702 Gender : Female
Ref By : Dr. APARNA PATIL Reported : 5/12/2023 5:58:35PM
Collected : 3/12/2023 12:33:00PM Report Status : Final
A/c Status : P
Test Report
AUTOIMMUNE BULLOUS DERMATOSES PROFILE

(IFA)
Desmoglien 1 Positive Negative
Desmoglein 3 Positive Negative
Titer 1:10
*456657702*
Page 1 of 5
.

Lab No. : 456657702 Age : 25 Years
Test Report
CYTOMEGALOVIRUS, INTERFERON GAMMA RELEASE ASSAY (IGRA)

(EIA)
CMV Antigen tube Minus Nil Tube 0.44 IU/mL <0.2
Mitogen tube Minus Nil Tube 3.04 IU/mL >0.5
Final Result Positive
Interpretation
---------------------------------------------------------------------------------------
| TUBE | REMARKS |
|-----------------------|----------------------------------------------------------------|
| Nil | Represents negative control which rules out the preexisting |
| | immune response due to heterophile antibody or non-specific |
| | gamma interferon production. |
|-----------------------|----------------------------------------------------------------|
| Mitogen minus Nil | Represents positive control demonstrating successful |
| | lymphocyte activity. |
|-----------------------|----------------------------------------------------------------|
| CMV Antigen minus Nil | Detects CD8+ lymphocyte reactivity, stimulated by CMV antigens.|
----------------------------------------------------------------------------------------
Result
--------------------------------------------------------------------------------------
| RESULT | REMARKS |
|---------------|----------------------------------------------------------------------|
| | Indicates presence of IFN-Gamma response to CMV antigens. It helps in|
| | dpredicting the risk of new and recurrent CMV disease following |
| Positive | transplantation (solid organ & haematological), guides in therapeutic|
| | decision making regarding prophylaxis and preemptive therapies, risk |
| | risk stratification of patients before transplantation and improving |
| | patient health. |
|---------------|----------------------------------------------------------------------|
| | Indicates absence of IFN-Gamma response to CMV antigens in patient’s |
| Negative | sample but does not exclude the possibility of CMV disease. Such |
| | patients undergoing Solid organ transplant are vulnerable to develop |
| | CMV infection |
|---------------|----------------------------------------------------------------------|
| Indeterminate | Indicates that IFN-Gamma Response to CMV antigens and Mitogen cannot |
| | be detected and may be related to the immune status of the individual|
--------------------------------------------------------------------------------------
Note
1. CMV serology is widely used pre-transplantation to establish risk of CMV complications post
PatientReportSCSuperPanel.SP_GENERAL_TEMPLATE01_SC (Version: 7)
*456657702*
Page 2 of 5
.

Lab No. : 456657702 Age : 25 Years
Test Report

transplantation, but has limited value post-transplantation. Pre-transplant negative CMV-IGRA
recipients who receive an organ from a CMV-seropositive donor have a 10-fold increase of CMV
replication compared to a pre-transplant CMV-IGRA Positive recipient.
2. Solid Organ Transplant patients with CMV-IGRA Positive result at completion of anti-CMV prophylaxis
have a significantly lower rate of late onset disease compared with those having a negative
CMV-IGRA result.
3. Higher risk transplant patients with a Positive CMV-IGRA result any time post prophylaxis have a 90%
chance of remaining free from CMV disease.
4. CMV-IGRA may prove useful in the prediction of spontaneous viral clearance compared to CMV
disease progression following elevations in CMV viraemia. Higher incidence of post solid organ
transplant CMV replication was seen in recipients with a negative CMV -IGRA result compared to
recipients with a Positive result.
5. CMV-IGRA is also used in haematological transplantation.
6. This test should not be used for diagnosis of CMV infection as a negative result does not exclude
CMV disease.
7. Test conducted on plasma.
Comment
Human Cytomegalovirus (CMV) represents one of the primary opportunistic pathogens and is a leading
cause of morbidity and mortality in Solid organ transplant recipients. It is a frequently occurring complication
of immunosuppression, particularly after transplantation. Pre-emptive or prophylactic antiviral therapy has
effectively reduced the impact and incidence of symptomatic CMV infection. Cell-mediated immunity (CMI),
and specifically CMV-specific CD4+ and CD8+ T-cell response, is able to control viral replication and thus
the onset of symptomatic infections.
CMV-IGRA in combination with quantitative monitoring of viral load in blood is recommended in CMV
Consensus Guidelines on the management of CMV in solid organ transplant patients. Transplant recipient
patients who have low or declining viral load in presence of positive CMV-IGRA may indicate a low risk of
disease and possible opportunity to stop antiviral therapy and adjust immunosuppressive treatment. On the
other hand transplant recipient patients who have high or increasing viral load in presence of negative
CMV-IGRA may indicate a high risk of CMV complications and the need to start or continue antiviral therapy,
begin cellular adoptive immunotherapy and adjust the immunosuppressive drugs.
In hematopoietic stem cell transplantation (HSCT), reactivation of latent virus is more common than
acquisition of primary infection. Preventing reactivation requires a robust T cell mediated immune reponse.
Immunosuppression and T cell depleting protocols used pre-HSCT, affect the risk of reactivation.
HLA-mismatched transplants where immunosuppression is increased and GVHD is more likely, are
*456657702*
Page 3 of 5
.

Lab No. : 456657702 Age : 25 Years
Test Report

particularly susceptible to reactivate CMV, and have a survival disadvantage. Pre-transplant screening and
pre-emptive therapy based on CMV viral load are employed routinely by transplant centres. Demonstration of
a CMV-specific T cell response may help to select patients who do not require continual treatment, assist
therapeutic decisions regarding anti-viral drug use (reducing unnecessary drug toxicities and
myelosuppressive side effects) and donor T cell infusions.
Dr Ajay Gupta Dr Sarita Kumari Lal Dr Shalabh Malik Dr Puneeta Singh

MD, Pathology MD, Pathology MD, Microbiology Ph.D (Microbiology)
Technical Director - Hematology & Consultant Pathologist Technical Director - Microbiology, Principal Research Scientist
Immunology Dr Lal PathLabs Ltd Infectious Disease Molecular & NRL - Dr Lal PathLabs Ltd
NRL - Dr Lal PathLabs Ltd Serology, Clinical Pathology
Dr Sunanda
MD, Pathology
Sr. Consultant Pathologist -
Hematology & Immunology
-------------------------------End of report --------------------------------

AHEEEHAPMKHJFOFNLGHALLPCBILLJCECCKLCIKPKNKEDFEFAPPAHEEEHA
BNFFFNBPAPBKFOMGFGECJOIPAOAHFHAKAKJOBCJCNLELNOJGMPBNFFFNB
GMDAEEFLLPPGBLGNHFIAAJHFJGBEHEDNLKPHENFLMKLMOEFLBLGDEHANP
DJHJAGFNBGLIELEPPIOELEPFANPLBLAFJIFEOBPAKKNJPDNLIFNBKEMEL
ICIEJLFIONNFDIABLBMGMHBDDENJMNCHKKMDECOIPLKGKPNGKFFFOMMKD
CKCBBEFCOECAMLHKIINNCIPBADHFOFAINDFCBKDLALIKOMNALNEJOOMKD
DBIMIJFFMLOFHPPIEOIBEHFHIHAFJBAKOFGPBLMEOJCHKNFNIJNNMDILD
BNFNAMFMBKOEPAKMAANHDHNILLBMFMBFKFCCAMNNIJKDKPNOBNFMAHILL
NKKPKIFCDAOGFEIBFPPIHNJKHOEFEKFBJFFKALPFOEBIOCNKDJPHNEKLJ
MOIIMFFCEHAJJDCGOBPOIDJCIDFKPNJHKEPHCBNLNKCKIGEOCMOKHIELL
IDIKNMFLGKKKNNCMPEABGJEEINMFNJIBJMFEBFOEONDMKPFKEPCIGKAMG
AKICGJFMMLDINGMMHPCJPPAEIEOPPFOEAMNPBLNOOLJAIANJNKONHDICL
MNNNNNEPCFADKKMAGCFLHOAHJBAHFHADPKPFCMNLMKJIPFNPAHFHAHIKL
APBBBPAPBLHAEBFJCMCKCIEFAGGCHHCAONFEOLPGOLMHNLNFEDFGHBKHH
HHHHHHHPHPHPHPPPPHHPPHPHPPPPPPPPPPPHHPHPPHHHPHPHHHHPHHPHP
*456657702*
Page 4 of 5
.

Lab No. : 456657702 Age : 25 Years
Test Report

IMPORTANT INSTRUCTIONS
ŸTest results released pertain to the specimen submitted .ŸAll test results are dependent on the quality of the sample received by the Laboratory .
ŸLaboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring Physician .ŸReport
delivery may be delayed due to unforeseen circumstances. Inconvenience is regretted .ŸCertain tests may require further testing at additional cost for
derivation of exact value. Kindly submit request within 72 hours post reporting.ŸTest results may show interlaboratory variations .ŸThe Courts/Forum
at Delhi shall have exclusive jurisdiction in all disputes /claims concerning the test(s) & or results of test(s).ŸTest results are not valid for medico legal
purposes.ŸThis is computer generated medical diagnostic report that has been validated by Authorized Medical Practitioner /Doctor.ŸThe report does
not need physical signature.
(#) Sample drawn from outside source.
If Test results are alarming or unexpected, client is advised to contact the Customer Care immediately for possible remedial action.
Tel: +91-11-49885050,Fax: - +91-11-2788-2134, E-mail: lalpathlabs@lalpathlabs.com
National Reference lab, Delhi, a CAP (7171001) Accredited, ISO 9001:2015 (FS60411) & ISO 27001:2013 (616691) Certified laboratory.
*456657702*
Page 5 of 5

Report

Uploaded by

Copyright:

Available Formats

Report

Uploaded by

Document Information

Original Description:

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Report

Uploaded by

Copyright:

Available Formats

Authenticity Check

Consulting Dr. : DR.APARNA PATIL Collected : 02-Dec-2023 / 14:54

HEPATITIS "B" SURFACE ANTIGEN (HBsAg)

Investigation Observed Value Unit Biological Reference Interval

Test Name Results Units Bio. Ref. Interval

AUTOIMMUNE BULLOUS DERMATOSES PROFILE

BP 180 Negative Negative

Desmoglien 1 Positive Negative

Desmoglein 3 Positive Negative

Test Name Results Units Bio. Ref. Interval

CYTOMEGALOVIRUS, INTERFERON GAMMA RELEASE ASSAY (IGRA)

CMV Antigen tube Minus Nil Tube 0.44 IU/mL <0.2

Mitogen tube Minus Nil Tube 3.04 IU/mL >0.5

Final Result Positive

Test Name Results Units Bio. Ref. Interval

Test Name Results Units Bio. Ref. Interval

Dr Ajay Gupta Dr Sarita Kumari Lal Dr Shalabh Malik Dr Puneeta Singh

-------------------------------End of report --------------------------------

Test Name Results Units Bio. Ref. Interval

Name : Ms. SAYLI NARALE Age : 25 Years

Test Name Results Units Bio. Ref. Interval

AUTOIMMUNE BULLOUS DERMATOSES PROFILE

BP 180 Negative Negative

Desmoglien 1 Positive Negative

Desmoglein 3 Positive Negative

Name : Ms. SAYLI NARALE

Test Name Results Units Bio. Ref. Interval

CYTOMEGALOVIRUS, INTERFERON GAMMA RELEASE ASSAY (IGRA)

CMV Antigen tube Minus Nil Tube 0.44 IU/mL <0.2

Mitogen tube Minus Nil Tube 3.04 IU/mL >0.5

Final Result Positive

Name : Ms. SAYLI NARALE

Test Name Results Units Bio. Ref. Interval

Name : Ms. SAYLI NARALE

Test Name Results Units Bio. Ref. Interval

Dr Ajay Gupta Dr Sarita Kumari Lal Dr Shalabh Malik Dr Puneeta Singh

-------------------------------End of report --------------------------------

Name : Ms. SAYLI NARALE

Test Name Results Units Bio. Ref. Interval

You might also like